Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $41.3600 (0.1%) ($40.2820 - $42.2500) on Wed. Dec. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.6% (three month average) | RSI | 63 | Latest Price | $41.3600(0.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 2.2% a day on average for past five trading days. | Weekly Trend | IOVA advances 4% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(48%) XBI(45%) ARKG(44%) IWO(42%) ARKK(39%) | Factors Impacting IOVA price | IOVA will decline at least -1.8% in a week (0% probabilities). VIXM(-23%) UUP(-16%) VXX(-12%) TBT(-6%) UNG(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.8% (StdDev 3.6%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $39.77(4%) | 10 Day Moving Average | $38.38(7.76%) | 20 Day Moving Average | $38.28(8.05%) | To recent high | 0% | To recent low | 47.3% | Market Cap | $6.057b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |